&lt;p&gt;Effect of Mental Health Problems on the Quality of Life in Children with Lupus Nephritis&lt;/p&gt;

Putera, Azwin Mengindra; Irwanto, Irwanto; Maramis, Margarita Maria; Prasetyo, Risky Vitria; Soemyarso, Ninik Asmaningsih; Noer, Mohammad Sjaifullah

doi:10.2147/ndt.s250373

Cited by 19 publications

(22 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The average caregiver stigma was 21.7±2.06, with a median value of 22. [15][16][17][18][19][20][21][22][23][24][25][26] There was no significant relation between caregiver stigma on the QoL of Indonesian The results showed no influence of caregiver stigma and caregiver burden on the QoL of Indonesian children with HIV (Tables 2 and 3).…”

Section: Discussionmentioning

confidence: 99%

<p>Quality-of-Life (QoL) of Indonesian Children Living with HIV: The Role of Caregiver Stigma, Burden of Care, and Coping</p>

Putera¹,

Irwanto²,

Maramis³

2020

HIV

Self Cite

View full text Add to dashboard Cite

Background: Treatment of children with HIV infection has increased rapidly by increasing the life span of HIV patients from baby to adult. Improving the quality-of-life (QoL) in children living with HIV is a priority of HIV management in children and caregivers of children living with HIV have important roles. Caregiver stigma, caregiver burden, and caregiver coping affect caregivers in treating children living with HIV. Objective: Analyzing the association of caregiver stigma, caregiver burden, and caregiver coping on QoL of Indonesian children living with HIV. Methods: Participants in this study were caregivers of Indonesian children living with HIV. Participants were measured for caregiver stigma, caregiver burden, caregiver coping, and QoL of Indonesian children living with HIV. The instrument used in measuring caregiver stigma was people living with HIV/AIDS and caregiver questionnaire, caregiver burden used Zarit Burden questionnaire, caregiver coping used F-COPES questionnaire, and QoL used PedsQL for children aged 2-18 years old. Measurement data were analyzed using logistic regression and independent t tests with P<0.05. Results: Indonesian children living with HIV in this study had an average age of 7.7±3.68 years and average participant age of 40.2±11.26 years. All participants stated that Indonesian children living with HIV tend to keep their health status confidential. Most QoL of Indonesian children living with HIV was good (71.7%), caregiver stigma value was 21.7±2.06, and caregiver burden level was moderate, of 50.9%. However, there was no significant association between caregiver stigma (β=0.064; P=0.548) and burden level (β=0.058; P=0.593) on QoL. On the other hand, caregiver coping value was 77.2±7.30, and there was a significant association of caregiver coping on QoL (β=−0.196; P=0.049). Conclusion: There is an association of caregiver coping on QoL of Indonesian children living with HIV, in which the higher the caregiver coping, the lower the QoL. Meanwhile, there is no significant association of caregiver stigma and burden on QoL of Indonesian children living with HIV.

show abstract

Section: Discussionmentioning

confidence: 99%

<p>Quality-of-Life (QoL) of Indonesian Children Living with HIV: The Role of Caregiver Stigma, Burden of Care, and Coping</p>

Putera¹,

Irwanto²,

Maramis³

2020

HIV

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Management Data and Drugs For Cslementioning

confidence: 99%

“…Management issues related to mental health, particularly anxiety, depression, and ineffective family coping, are frequent in children and adolescents with cSLE or lupus nephritis patients and may impact their health-related quality of life [ 131 , 132 ]. Although there is a lack of controlled studies assessing mental issues in cSLE, studies report depression and anxiety symptoms to be present in 37% and 30% of patients, respectively [ 133 ], and to be more frequent during the induction phase of the treatment [ 131 ]. Identifying targets for improving mental health care, such as developed mental health training for pediatric rheumatologists and integration of medical and mental health services, was proposed by CARRA (Childhood Arthritis and Rheumatology Research Alliance) [ 132 ].…”

Section: Management Data and Drugs For Cslementioning

confidence: 99%

An Update on the Management of Childhood-Onset Systemic Lupus Erythematosus

et al. 2021

View full text Add to dashboard Cite

Childhood-onset systemic lupus erythematosus (cSLE) is a prototype of a multisystemic, inflammatory, heterogeneous autoimmune condition. This disease is characterized by simultaneous or sequential organ and system involvement, with unpredictable flare and high levels of morbidity and mortality. Racial/ethnic background, socioeconomic status, cost of medications, difficulty accessing health care, and poor adherence seem to impact lupus outcomes and treatment response. In this article, the management of cSLE patients is updated. Regarding pathogenesis, a number of potential targets for drugs have been studied. However, most treatments in pediatric patients are off-label drugs with recommendations based on inadequately powered studies, therapeutic consensus guidelines, or case series. Management practices for cSLE patients include evaluations of disease activity and cumulative damage scores, routine non-live vaccinations, physical activity, and addressing mental health issues. Antimalarials and glucocorticoids are still the most common drugs used to treat cSLE, and hydroxychloroquine is recommended for nearly all cSLE patients. Disease-modifying antirheumatic drugs (DMARDs) should be standardized for each patient, based on disease flare and cSLE severity. Mycophenolate mofetil or intravenous cyclophosphamide is suggested as induction therapy for lupus nephritis classes III and IV. Calcineurin inhibitors (cyclosporine, tacrolimus, voclosporin) appear to be another good option for cSLE patients with lupus nephritis. Regarding B-cell-targeting biologic agents, rituximab may be used for refractory lupus nephritis patients in combination with another DMARD, and belimumab was recently approved by the US Food and Drug Administration for cSLE treatment in children aged > 5 years. New therapies targeting CD20, such as atacicept and telitacicept, seem to be promising drugs for SLE patients. Anti-interferon therapies (sifalimumab and anifrolumab) have shown beneficial results in phase II randomized control trials in adult SLE patients, as have some Janus kinase inhibitors, and these could be alternative treatments for pediatric patients with severe interferon-mediated inflammatory disease in the future. In addition, strict control of proteinuria and blood pressure is required in cSLE, especially with angiotensin-converting enzyme inhibitor and angiotensin receptor blocker use.

show abstract

“…Family crisis oriented personal evaluation scales (F-COPES) are tools used to assess family coping consisting of 30-item questions. The F-COPES consists of 5 sub-scales (obtaining social support, seeking spiritual support, reframing, mobilizing family support, and passive assessments) which were assessed using Likert's scale [ 26 , 27 ]. The Indonesian version of F-COPES was declared valid and reliable with a value of α = 0.89 [ 27 , 28 ].…”

Section: Methodsmentioning

confidence: 99%

The role of house dust mite immunotherapy in Indonesian children with chronic rhinosinusitis allergy: A randomized control trial

Putera

Hikmah

Endaryanto

et al. 2021

Heliyon

Self Cite

View full text Add to dashboard Cite

Background Chronic rhinosinusitis allergy (CRA) is a disease that is commonly found in children and is mostly caused by allergy to house dust mites (HDM). The use of HDM immunotherapy can be considered in children with allergies. Objectives Analyzing the impact of mite immunotherapy on disease burden in Indonesian children with CRA. Methods A randomized control trial study was conducted to participants in 2 groups, namely the immunotherapy group (n = 25) and the non-immunotherapy group (n = 25). Participants were given HDM immunotherapy for 14 weeks, which was given once per week. Participants during therapy were evaluated for rhinosinusitis symptoms and measured their immunity status (specific IgE), sleep quality (SDSC), quality of life (SN5), and family coping (F-COPES) pre-post therapy. Statistical analysis used in this study included paired t-test, Wilcoxon test, independent t-test, or Mann Whitney test with p < 0.05. Results The value of specific IgE in the immunotherapy group was 4.12 ± 7.75 kU/l (pre-test) and 1.52 ± 2.42 kU/l (post-test; p < 0.001), while in the non-immunotherapy group was 1.47 ± 3.28 kU/l (pre-test) and 1.18 ± 2.81 kU/l (post-test; p = 0.317). The SDSC value in the immunotherapy group was 42.16 ± 2.75 (pre-test) and 30.32 ± 3.22 (post-test; p < 0.001), while in the non-immunotherapy group was 41.92 ± 2.75 (pre-test) and 41.84 ± 2.87 (post-test; p = 0.987). The F-COPES value in the immunotherapy group was 101.56 ± 5.78 (pre-test) and 105.20 ± 4.31 (post-test; p = 0.015), while in the non-immunotherapy group was 100.36 ± 9.63 (pre-test) and 99.96 ± 9.98 (post-test; p = 0.224). The SN-5 value in the immunotherapy group was 30.04 ± 2.78 (pre-test) and 11.00 ± 2.33 (post-test; p < 0.001), while in the non-immunotherapy group was 30.04 ± 2.78 (pre-test) and 30.04 ± 2.78 (post-test; p = 0.767). There was a significant comparison between the immunotherapy group and the non-immunotherapy group on the specific IgE ( p = 0.013), SDSC ( p < 0.001), and SN-5 ( p < 0.001) values. Meanwhile, there was no significant difference in the F-COPES value ( p = 0.129). Conclusions The administration of HDM immunotherapy can improve the participant's immunity, quality of life, and sleep disorder.

show abstract

<p>Effect of Mental Health Problems on the Quality of Life in Children with Lupus Nephritis</p>

Cited by 19 publications

References 52 publications

<p>Quality-of-Life (QoL) of Indonesian Children Living with HIV: The Role of Caregiver Stigma, Burden of Care, and Coping</p>

<p>Quality-of-Life (QoL) of Indonesian Children Living with HIV: The Role of Caregiver Stigma, Burden of Care, and Coping</p>

An Update on the Management of Childhood-Onset Systemic Lupus Erythematosus

The role of house dust mite immunotherapy in Indonesian children with chronic rhinosinusitis allergy: A randomized control trial

Contact Info

Product

Resources

About